Heart-targeted amelioration of sepsis-induced myocardial dysfunction by microenvironment responsive nitric oxide nanogenerators in situ

Minzhi Ouyang¹, Xiangnan Ouyang¹, Zefang Peng², Minghui Liu¹, Ganqiong Xu¹, Zhen Zou³, Ming Zhang¹* and Quanliang Shang¹*

Abstract

Background: A balanced endogenous level of bioavailable nitric oxide (NO) plays a key role in maintaining cardiovascular homeostasis. The bioactive NO level in the cardiomyocytes was much reduced during sepsis. However, it is clinically challenging for the NO gas therapy due to the lack of spatial and temporal release system with precise control. The purpose of this study is to design a NO-releasing biomaterial with heart-targeted capability responsive to the infectious microenvironment, thus ameliorating lipopolysaccharide (LPS)-induced cardiac dysfunction.

Results: The heart-targeted NO delivery and in situ releasing system, PCM-MSN@LA, was synthesized using hollow mesoporous silica nanoparticles (MSN) as the carrier, and L-arginine (LA) as the NO donor. The myocardial delivery was successfully directed to heart by specific peptide (PCM) combined with low-intensity focused ultrasound (LIFU) guidance. The myocardial system synthesized NO from the LA released from PCM-MSN@LA in the presence of increased endogenous nitric oxide synthase (NOS) activity induced by LPS. This targeted NO release in situ achieved extraordinary protective effects against LPS-challenged myocardial injury by reducing the recruitment of inflammatory cells, inhibiting oxidative stress and maintaining the mitochondria integrity. In particular, this protection was not compromised by simultaneous circulation collapse as an adverse event in the context.

Conclusions: PCM-MSN@LA + LIFU exhibited extraordinary cardioprotective effects against severe sepsis in the hearts of LPS-treated animals without the side effect of NO diffusion. This technology has great potential to be served as a novel therapeutic strategy for sepsis-induced myocardial injury.

Keywords: Sepsis, Targeted delivery, Microenvironment change, Gas therapy, Cardiac dysfunction alleviation

Background

Sepsis is caused by the dysregulated host response to infection accompanied by life-threatening organ dysfunction. The mortality of sepsis in 2017 was approximately 11.0 million representing 19.7% of deaths worldwide [1, 2]. Lately, the COVID-19 pandemic has been recognized as a public health emergency of global concern with sepsis as an overlooked killer in COVID-19 patients [3]. Sepsis-related organ dysfunction, oxidative stress, and inflammation are key features of severe sepsis and septic shock, leading to multi-organ failure and high mortality.

LPS-induced myocardial injury plays a central role in increasing mortality. For instance, the mortality risk exceeded 70–90% in patients who developed heart failure in sepsis [4–6]. The mechanisms involved in septic cardiomyopathy include dysregulated inflammatory response, oxidative stress, and mitochondrial dysfunction. This study was designed to design a NO-releasing biomaterial with heart-targeted capability responsive to the infectious microenvironment, thus ameliorating LPS-induced cardiac dysfunction through targeted delivery of NO in situ.

The heart-targeted NO delivery and in situ releasing system, PCM-MSN@LA, was synthesized using hollow mesoporous silica nanoparticles (MSN) as the carrier, and L-arginine (LA) as the NO donor. The myocardial delivery was successfully directed to heart by specific peptide (PCM) combined with low-intensity focused ultrasound (LIFU) guidance. The myocardial system synthesized NO from the LA released from PCM-MSN@LA in the presence of increased endogenous nitric oxide synthase (NOS) activity induced by LPS. This targeted NO release in situ achieved extraordinary protective effects against LPS-challenged myocardial injury by reducing the recruitment of inflammatory cells, inhibiting oxidative stress and maintaining the mitochondria integrity. In particular, this protection was not compromised by simultaneous circulation collapse as an adverse event in the context.

Conclusions: PCM-MSN@LA + LIFU exhibited extraordinary cardioprotective effects against severe sepsis in the hearts of LPS-treated animals without the side effect of NO diffusion. This technology has great potential to be served as a novel therapeutic strategy for sepsis-induced myocardial injury.

Keywords: Sepsis, Targeted delivery, Microenvironment change, Gas therapy, Cardiac dysfunction alleviation

© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
stress and mitochondrial damage [7]. Although advances in understanding the mechanism have been achieved, drug-resistant bacterial mutants and the complicated pathophysiology have hampered the clinical outcomes of septic cardiomyopathy. Reprogramming of the septic heart microenvironment has become an indispensable supportive treatment for relieving heart failure by maintaining cardiac homeostasis in the context of sepsis.

Nitric oxide (NO) is an important signalling molecule in cardiovascular diseases. NO donors successfully ameliorated the impaired myocardial microenvironment by inhibiting inflammatory cell recruitment, preventing excessive oxidant responses and stabilizing mitochondrial homeostasis [8–10]. Following the reactions of peroxynitrite (O₂⋅− + NO → ONOO−), elevated reactive oxygen species (ROS) in sepsis could consume NO, consequently abrogating NO bioavailability and deteriorating organ dysfunction [11, 12]. Thus, increasing the NO content at the early stage of sepsis has the potential to maintain NO activity and further reduce ROS production without the risk of producing excessive peroxynitrite (ONOO−). However, the delivery and employment of NO to the myocardium have remained challenging, mainly due to the random diffusion and reactive chemical nature of NO in the circulation. Besides, taking long-term organic nitrates led to cyanide accumulation in the body [13]. As an alternative, NO-donating nanoparticles have attracted extensive attention due to their stability in circulation enabling modification by a variety of substances. To ensure the therapeutic effects of NO, the nanoparticles should target the myocardium precisely followed by a stimuli-responsive NO release.

MSNs are used in this study for LA conjugation to enhance the stability of the NO donor. Attaching specific moieties such as peptides to the surface of MSN@LA nanoparticles could provide robust targeted delivery capability [14]. PCM, a 20-mer peptide (WLSEAGPVT-VRALRGTGSw) isolated by phage display, could bind to primary cardiomyocytes with a 180-fold higher efficiency than the control, at the same time showing great specificity [14]. Therapeutic ultrasound, known as low-intensity focused ultrasound (LIFU), has been recommended as an efficient approach to further improve targeted delivery to the myocardium [16, 17]. When exposed to the LIFU irradiation, the uptake of bioactive agents was enhanced in specific tissues due to a transient increase in the cell membrane permeability [18, 19]. Therapeutic ultrasound usually has a frequency range of 0.75–3 Hz, within which the frequency of 1–2 Hz has been mostly used [19]. Therefore, the dual system employing the PCM-mediated targeting and LIFU irradiation is promising to precisely transfer LA to the myocardium.

Various polymer- and lipid-based NO donor carriers have shown some benefits in promoting vasodilation in stroke [20], restoring glucose homeostasis [21] or treating cancer [22, 23], yet not related to septic cardiomyopathy management. As known, the NO serves as a cellular messenger in living cells synthesized mainly from L-arginine by nitric oxide synthases (NOSs). There are three isoforms of the enzyme including endothelial (eNOS), neuronal (nNOS), and inducible NOS (iNOS) [24]. During sepsis, the infectious environment exhibits pathological characteristics different from the normal scenario, in which the elevation of NOs expression is a distinct one. In the early phase of sepsis, the iNOS and eNOS both increased nearly 2–3 times over the physiological level [25]. On this basis, it is expected that LA, a natural NO donor with excellent biocompatibility, can liberate NO in a NOS-rich microenvironment. Therefore, the NO-donating nanoparticles designed in this context are expected to have an essential function in cardiovascular protection responding to sepsis (Fig. 1).

In summary, we have successfully designed and utilized a myocardium-targeting nanoscale carrier system that could generate NO in the heart without causing nitrate/nitrite accumulation in the circulation. In the early phase of sepsis, this targeted gas therapy efficiently improved the myocardial function by alleviating the inflammatory response, reducing ROS production, as well as protecting myocardial mitochondria. This strategy is very promising to be applied as a timely treatment to ameliorate the septic microenvironment and enhance antibiotic efficacy, thus boosting the cardioprotective effects during sepsis.

Results

Characterization of PCM-MSN@LA

PCM-MSN@LA is featured as spherical nanoparticles (Fig. 2a) with good scattering (Fig. 2b). Conjugation of MSNs to PCM leads to increased diameters from 132.67 nm to 179.33 nm whereas the surface charge returned to a negative position of -6.23 mV (Fig. 2c, d). The nanoparticles showed a hexagonal array that could be indexed as (100), (110), and (200) Bragg peaks in the powder X-ray diffraction (XRD) pattern (Additional file 1: Fig. S1). Nitrogen adsorption–desorption measurements of the specific surface area of MSN-NH2, PCM-MSN and PCM-MSN@LA showed substantial difference in absorption isotherms as 764.332 m² g⁻¹, 661.83 m² g⁻¹ and 62.07 m² g⁻¹, respectively, indicating that some channels of mesoporous nanoparticles were occupied by PCM and filled with LA (Fig. 2e). This result demonstrated successful PCM and LA grafting to MSN nanoparticles, in which
Fig. 1  NO liberation in septic heart from PCM-carried and L-arginine loaded porous MSN, named PCM-MSN@LA, combined with the LIFU, preventing the myocardial dysfunction.

Fig. 2  Physicochemical characterization of PCM-MSN@LA.  
(a) TEM images of PCM-MSN@LA particles and the morphology of PCM-MSN@LA particles (scale bar = 20 nm).  
(b) TEM and SEM images of PCM-MSN@LA particles (TEM: scale bar = 0.5 μm; the left upper corner image: scale bar = 50 nm; SEM: scale bar = 1 μm).  
(c) Variation of MSNs after each modification in size and zeta.  
(e) The specific surface area of different samples analyzed by N₂ adsorption–desorption method.  
(f, g) Variation of particles in size and zeta of PCM-MSN@LA in deionized water from 0 to 28 days measured using DLS.
PCM and LA accounted for nearly 39.7% and 20.2%, respectively, of the total nanoparticle weight measured by TG analysis (Additional file 1: Fig. S2). In vitro stability of PCM-MSN@LA is a critical physicochemical property, which was retained at high levels without notable changes in size distribution or zeta potential during 28 days of storage at 37 °C (Fig. 2f, g).

LA encapsulation and release profiles of PCM-MSN@LA and the cytotoxicity assay
Within the 10 mg of PCM-MSN@LA, there was 2.4 mg of LA in total measured by UV–vis (Additional file 1: Fig. S3), of which 11.5% and 16.9% were released in HEPES at pH 7.35–7.45 and pH 7.00–7.30, respectively, within 600 min. The release efficiency of LA was remarkably improved via LIFU to nearly 25.6% at pH 7.35–7.45 and 35.3% at pH 7.00–7.30. (Fig. 3a, b). There was no detectable cytotoxicity of PCM-MSN@LA to cardiomyocytes at concentrations below 1 mg mL⁻¹ (Fig. 3c). Comparable tissue architecture in major organs, including lungs, livers, spleens, kidneys and hearts of the mice, was observed before and 24 h after intravenous injection of 50 mg kg⁻¹ PCM-MSN@LA, the 50 mg kg⁻¹ PCM-MSN@LA treated mice showed minor change (Fig. 3e). Furthermore, there was no obvious hemolysis visualized after incubation of the nanoparticles with blood for 3 h at various concentrations up to 3200 mg mL⁻¹ (Fig. 3d).

These results demonstrate the safety profile of PCM-MSN@LA to cardiomyocytes.

Cellular uptake of PCM-MSNs in vitro and PCM-MSN@LA + LIFU biodistribution in vivo
PCM showed a high affinity for cardiomyocytes as confirmed by robust green FITC-PCM signals co-localized with red PE-α-SA signals as a cardiomyocyte-specific marker in the PCM-MSN group (Fig. 4). In contrast, there were significantly reduced green FITC signals in the scrambled peptide group with cardiomyocytes or scarce in the HepG2 groups with PCM-MSNs, suggesting the specific affinity of PCM for cardiomyocytes.

The transpotation capability and efficiency of PCM to the heart with or without LIFU were assessed in vivo. Red fluorescence signals representing nanoparticles were visualized in multiple major organs. In comparison to the control MSN group, there were significantly increased signals, with nearly 60-fold higher fluorescence intensity, in the heart of mice with PCM-MSN. It indicates PCM mediated efficient transportation of MSN targeting the heart. The targeting efficiency was further boosted via LIFU with a sevenfold increase of fluorescence intensity visualized in the PCM-MSN + LIFU group compared to the PCM-MSN one (Fig. 5a, b). LIFU irradiation enables PCM-MSN to penetrate through cardiac microvessels more easily to reach the myocardium. This effect
is specific to the heart as most other organs or tissues, including the liver, kidneys, lungs and spleen, showed substantially less distribution of PCM-MSN (Fig. 5c, d). Altogether it demonstrates that the combination of PCM and LIFU strategies ensured efficient nanoparticle transportation to the heart and efficiently improved the delivery to cardiomyocytes.

**NO production from the myocardium-targeted NO release system in cardiomyocytes**

NO synthase is required to generate NO in vivo. Upon LPS stimulation, the endogenous expression of NOS isoforms, iNOS and eNOS, was remarkably elevated in cardiomyocytes from 30 min up to 12 h with peaks at 2 h and 6 h, respectively (Fig. 6a–c).

The NO production capacity of PCM-MSN@LA in combination with LIFU in cardiomyocytes was further studied by measuring NO levels through Griess assay and fluorescence microscopy after DAF-FM DA staining. There was no obvious NO increase in cardiomyocytes with PCM-MSN@LA in the absence of LPS treatment, which levels were similar to the untreated cells. On the contrary, the nitrite levels were significantly upregulated in the presence of LPS treatment in a dose-dependent manner (Fig. 6d). Likewise, DAF-FM DA staining detected substantially enhanced green fluorescence signals, which represented NO production in LPS-induced cardiomyocytes, in the presence of 75 μg mL⁻¹ PCM-MSN@LA combined with LIFU within 6 h, further supporting the evidence of NO release (Fig. 6e). These data indirectly suggest that PCM-MSN@LA could produce NO effectively in the context of infection. Interestingly, although extraordinary upregulation was observed after LPS treatment, the absolute NO levels remained low in the cardiomyocytes with PCM-MSN@LA. The absolute nitrite level was 0.5 μM 2 h after LPS stimulation, even co-incubated with PCM-MSN@LA, the absolute nitrite level was 0.56 μM only. This low concentration is critical for the influence of NO on the heart to maintain cardiovascular homeostasis [24].

**PCM-MSN@LA alleviates LPS-induced injury in cardiomyocytes**

LPS is able to induce massive damage in tissues and organs. This effect can be alleviated by PCM-MSN@LA, and, to a further extent, by PCM-MSN@LA + LIFU in cardiomyocytes with the cell viabilities improved from 62 to 72% and 80%, respectively (Fig. 7a). Evaluation of apoptosis by the CCK-8 assay and TUNEL staining revealed severely injured cardiomyocytes induced by LPS with or without PCM-MSN (Fig. 7b). Nevertheless, the percentage of apoptotic cells has been substantially decreased by PCM-MSN@LA, and to a greater extent, by PCM-MSN@LA + LIFU (Fig. 7c). To confirm the effect of LIFU-mediated PCM-MSN@LA on ROS scavenging, the
intracellular ROS probe, DCFH-DA, was used. As shown in Fig. 7d, the average ROS level in cardiomyocytes treated with LPS has decreased after PCM-MSN@LA incubation with or without LIFU for 6 h. However, this reduction was not observed in cells with PCM-MSN only. This finding suggested that ROS reduction was potentially associated with NO release in the cardiomyocytes.

**Myocardium-targeted NO release alleviated cardiac apoptosis and improved survival rate during sepsis**

The protective effect of targeted NO release on injured myocardium during LPS treatment was evaluated by the TUNEL assay. Numerous necrotic cells in brown were detected across the cardiac tissue upon LPS administration (Fig. 8a). The degree of necrosis was effectively lessened by PCM-MSN@LA, and to a greater degree by PCM-MSN@LA + LIFU, yet not by PCM-MSN or MSN@LA (Fig. 8a, b). Simultaneously, the levels of caspase-3 protein, which is an apoptotic index with upregulated expression during necrosis, displayed a similar tendency (Fig. 8c, d). The cardiac function is closely related to the survival rate. Survival analysis confirmed the highest survival rate in the PCM-MSN@LA + LIFU group, followed by the PCM-MSN@LA group to a lesser extent (Fig. 8e). These data indicate that a precise and efficient release of LA at a low level could facilitate the protection of the myocardium in the sepsis model.

**Cardiovascular protection by localized NO release during sepsis**

To verify whether precisely targeted NO release could prevent heart dysfunction during sepsis, several serum markers including cTnI, CK-MB, and LDH were measured. In addition, the echocardiography (ECG), blood
pressure, and histological morphology of all animals were examined.

There was a ninefold higher expression of cTnI and CK-MB (3739.9 ± 182.3 vs. 430.4 ± 27.2; 2026.3 ± 370.2 vs. 253.9 ± 57.6), and a sixfold increase in LDH expression (1344.4 ± 240.5 vs. 259.9 ± 50.5), in the serum of the mice injected with LPS, as compared to the control group of normal mice. Treatments with PCM-MSN or MSN@LA had no apparent effects on the expression of these markers compared with the LPS group. Nevertheless, PCM-MSN@LA injection, especially combined with LIFU irradiation, notably dropped the levels of these markers with the reduction rates of 37%, 31% and 21% in the former group, and 53%, 47% and 39% in the other one (Fig. 9a–c) for cTnI, CK-MB, and LDH, respectively.

Along with the changes in the serum markers, ECG analysis showed significantly higher EF and FS, whereas lower LV VOLs and LVESD, in the PCM-MSN@LA-treated mice with slightly better parameters in the mice receiving LIFU simultaneously, whereas no much difference in the other groups (Fig. 9d–i). This was also observed via the M-mode in the short-axis view (Fig. 9k).

Edema and inflammatory cell infiltration accompanied with disorganized myocardial fibers were presented in the hearts of the LPS group, as shown by H&E analysis (Fig. 9l). The degree of edema and fibrosis in the hearts was substantially relieved in the presence of PCM-MSN@LA and PCM-MSN@LA + LIFU. This suggested that the precise location of LA to the heart followed by its conversion to NO resulted in cardiac protection in the sepsis mouse model.

Hypotension is another major hemodynamic disorder that is closely linked to sepsis-related mortality. All septic mice exhibited lower blood pressure than the controls despite of fluid resuscitation. The PCM-MSN treatment did not recover the blood pressure or, even worse, the MSN@LA aggravated this disorder in related animals. PCM-MSN@LA, particularly plus LIFU, significantly mitigated LPS-induced hypotension (Fig. 9j). Accordingly, this cardiovascular recovery was not associated

---

**Fig. 6** Assessment of NO generation from PCM-MSN@LA in the cardiomyocytes with or without LIFU in vitro. a The expression of iNOS and eNOS in LPS-incubated cardiomyocytes from 5 min to 24 h. b, c The quantitative analyses of iNOS and eNOS expression (n = 6). Data were presented as mean ± SD. *P < 0.05; **P < 0.01. d Relative nitrite concentration from different doses of PCM-MSN@LA in cardiomyocytes with or without LPS (n = 6). Data were presented as mean ± SD. *P < 0.05; **P < 0.01. e Confocal images of cardiomyocytes stained by DAF-FM DA following 75 μg mL⁻¹ PCM-MSN@LA irradiated with LIFU over time (scale bar = 100 μm)
with other vasodilatory side effects in the animals. Thus, this elaborately designed strategy of PCM-MSN@LA in combination with LIFU irradiation could efficiently alleviate myocardial dysfunction in the sepsis model.

The mechanism of myocardium-targeted NO release on LPS-induced cardiac dysfunction
The potential mechanism of in vivo myocardium protection by PCM-MSN@LA + LIFU during sepsis can be attributed to the following three reasons: (1) regulating the myocardial inflammatory response; (2) ameliorating oxidant stress; (3) maintaining mitochondrial function. These mechanisms were investigated in this context.

The general effects of LPS in the body have been described as overwhelming accumulation of inflammatory cytokines including IL-1β, IL-6, IL-18 and TNF-α, and upregulated expression of inflammatory-associated proteins including NLRP3 and NF-kB P65. The same actions have been also observed in the animals treated with LPS in this context (Fig. 10a–g). Delivery of PCM-MSN@LA, especially under LIFU irradiation, significantly eased extensive inflammatory response in the heart with statistically significant reduction of IL-1β, IL-6, IL-18 and TNF-α mRNA, as well as NLRP3 and NF-kB P65 protein expression. Similar changes were observed in Gr-1 expression, which is associated with the functional performance of neutrophils. There was large amount of Gr-1+ neutrophils with brown nuclei recruited to the myocardium of LPS-treated mice. The amount of Gr-1+ neutrophils was also largely decreased in the groups receiving PCM-MSN@LA and PCM-MSN@LA + LIFU, yet remained almost the same in those with other treatments. It indicates the PCM-MSN@LA + LIFU remarkably limited the accumulation of functional neutrophils in the myocardium in the sepsis animals (Fig. 10h, i).
ROS generation was assessed using MDA and DHE analyses. LPS-induced elevation of MDA levels in the cardiac was decreased by PCM-MSN@LA with statistical significance (Fig. 11a). Oxidative stress in the myocardium measured by DHE also showed a concomitant increase in LPS treated mice, which was significantly suppressed by PCM-MSN@LA. Moreover, both ROS and oxidative stress activities were the least in all groups with different treatments. Collectively, PCM-MSN@LA+LIFU exhibited excellent antioxidant activity against the ROS burden after myocardial injury in the LPS-induced sepsis model (Fig. 11b, c).

Drp1 and Mfn 2 are two regulatory enzymes that control mitochondrial fission and fusion [26, 27]. They are closely related to mitochondrial function and can be affected by LPS with upregulated Drp1 and downregulated Mfn 2 levels in LPS-treated mice. As expected, these dysregulations can be reversed by PCM-MSN@LA, and LIFU to a greater extent, yet not by PCM-MSN or MSN@LA injections (Fig. 12a–c). Consistent with the dysregulated enzyme levels, impaired mitochondria structure of various sizes, vacuolar changes and partial cristae disruptions, along with swollen damaged cardiac muscle fibres, were further investigated in LPS group by TEM analysis (Fig. 12d). These structural impairments were substantially attenuated only in the mice with PCM-MSN@LA, particularly in the presence of LIFU irradiation, suggesting that PCM-MSN@LA+LIFU could effectively restore mitochondrial function, probably via efficient release of NO in the cardiac.

**Discussion**

Cardiac dysfunction is an early and fatal complication of sepsis [12]. Although there has been great interest in the development of NO therapy in the treatment of cardiovascular diseases, the therapeutic NO strategy for modulation of myocardial function in sepsis has not been practically used yet, due to the rapid diffusion
Fig. 9 (See legend on previous page.)
of NO as a major drawback [28]. We have developed a non-toxic and efficient NO donor delivery system, PCM-MSN@LA + LIFU, to precisely control NO release during sepsis so as to protect cardiac function from LPS injury. This is the first time to report the efficiency and safety of a targeted NO donor delivery system in the septic model.

The targeted delivery of NO is based on a MSN-conjugated 20-mer peptide, namely PCM, with an excellent binding capacity to the heart. In vitro study in cell lines and in vivo study using different tissues both demonstrated the specific affinity of PCM-MSN to cardiomyocytes as compared to the scramble control. The strong PCM-MSN signal distributed in the mouse heart, which was threefold weaker in the control animals, suggested that PCM had efficiently guided nanoparticles to the heart. Thus it enhanced tissue-specific uptake of MSN as consistent with previous publications [15, 16, 29, 30].

McGuire et al. [15] developed a quantitative real-time PCR assay to show that the PCM had a nearly 50-fold increase in cardiac selectivity over the control 20-mer peptides. Apart from the high selectivity, other advantages of peptides include lower molecular weight, easier synthesis, lower cytotoxicity and better conjugation capability onto nanocarriers compared to antibodies [14]. On the other hand, a LIFU-triggered drug delivery system could be a potential solution for liberating a drug from its formulation at a focused site. Ultrasound with high US energy, which is also called high-intensity focused US (HIFU), only induced limited delivery to the heart. Conversely, noninvasive LIFU with low energy exhibited considerable tissue-penetrating ability. Thus, it has been

![Fig. 10](image-url)
Myocardium-targeted NO release effectively relieved LPS-induced myocardial antioxidants stress.

**Fig. 11**

- **a** Measurement of MDA concentration (n = 8). Data were presented as mean ± SD, *P < 0.05; **P < 0.01.
- **b** Representative image of DHE stained heart sections with a ROS fluorescent probe. DAPI (blue, nuclei); ROS positive (red) (scale bar = 200 μm).
- **c** Quantitative analysis of ROS fluorescent intensity (n = 8). Data were presented as mean ± SD, *P < 0.05; **P < 0.01.

Myocardium-targeted NO release effectively prevented mitochondrial dysfunction in the myocardium of the LPS-induced sepsis model.

**Fig. 12**

- **a** Expression of mitochondrial mediator proteins Drp1 and Mfn 2.
- **b, c** Quantitative analysis of Drp1 and Mfn 2 expression (n = 8). Data were presented as mean ± SD, *P < 0.05; **P < 0.01.
- **d** TEM analysis of myocardial sections (scale bar = 1 μm).
intensively studied for therapy and diagnostic imaging purposes [16–18, 31]. Consistent with an optimised frequency, we have set 1.0 W/cm²-20% power as the LIFU parameter [19]. Indeed, LIFU irradiation facilitated successful targeting and delivery of PCM-MSN@LA to the cardiac tissue resulting in more NO release yet without inducing prominent side effects on the circulation.

There is another concern with the level of NO production. NO is produced in various types of cells by NOS isoforms through the oxidation of LA. NO deficiency is critically associated with the onset and development of cardiovascular disease [10, 32]. Our results of NO generation in situ demonstrated that different doses of PCM-MSN@LA, particularly under the LIFU irradiation, induced relative changes in NO levels in cardiomyocytes compared to other treatments. Under normal circumstances, there is only a low expression of eNOS without any significant modulation in NO generation. In the situation of sepsis, NO generation related to PCM-MSN@LA was closely associated with increased levels of iNOS and eNOS, indicating that the nanoparticles mediated NO generation in this specific context, which in turn acted on the body. Secondly, the data from the UV–vis assay showed that with exposure to LIFU irradiation, 25.6% of LA release from PCM-MSN@LA nanoparticles in pH 7.35–7.45 solutions 35.3% in pH 7.00–7.30 solutions. This confirms the absolute NO level generated from the PCM-MSN@LA + LIFU treatment in the acidic micro-environment of sepsis was not excessive. The biological effects of NO highly relied on the absolute concentration of NO [33]. The absolutely low level of NO was associated with some of the most important immunopathologies in cardiovascular diseases with a direct influence on cardiovascular dysfunction [10, 25, 34]. Thus, the sequential generation system of NO responsive to the septic microenvironment showed a very promising therapeutic strategy for the heart in this context.

In addition, our data clearly showed the central role of NO generated from the nanoparticles in inhibiting cardiomyocyte apoptosis and ameliorating cardiac function in severe sepsis. The therapeutic effects of NO-releasing nanoparticles in the sepsis scenario could be attributed to several mechanisms including immune regulation, ROS reduction and mitochondrial modulation. Excessive cytokines and inflammatory factors induced by LPS had been remarkably decreased by the PCM-MSN@LA + LIFU treatment, which was consistent with previous research [35, 36]. NLRP3 and NF-κB P65 are two important components of the inflamasome. Stimulation of NF-κB P65 together with NLRP3 activation led to a lethal consequence of cardiac dysfunction [37]. Thus, downregulation of NLRP3 and NF-κB P65 expressions with simultaneous inhibition of proinflammatory cytokines could effectively improve heart function in the sepsis model. The observation of much fewer Gr-1⁺ neutrophils in the myocardium further confirmed that NO played a central role in neutrophil migration in the presence of PCM-MSN@LA + LIFU.

LPS leads to the worsening of oxidative stress, which promoted proinflammatory immune reactions and severe damage to mitochondrial metabolism [7, 38]. The reduction of NO bioavailability was associated with excessive ROS generation which was also witnessed in this context. We assumed that NO production was capable to recover the balance with retained bioactivity. Consequently, bioactive NO could modulate NADPH oxidase and regulate cardiac mitochondrial respiration to protect the heart away from neutrophil infiltration and further mitigate the ROS burden [25, 39–42]. As predicted, the application of PCM-MSN@LA + LIFU liberated bioactive NO in the myocardium, exhibiting a robust inhibitory effect on LPS-induced oxidative stress as was reflected by reduced MDA levels and significantly decreased DHE-positive cells in the sepsis animals.

The high mitochondrial density allows instant and fast energy production in cardiomyocytes [4]. Mitochondrial dysfunction in sepsis was manifested as elevated Drp1 expression and diminished Mfn2 expression. PCM-MSN@LA + LIFU therapy showed extensive mitochondrial protection by diminishing the Drp1 as well as elevating the Mfn2 expression. In addition, the morphology and density were also much improved after PCM-MSN@LA + LIFU treatment as confirmed by TEM analysis.

Despite decades of research regarding the effects of NO donor in sepsis, there has been only limited clinical application of NO treatment for cardiac sepsis. One caveat is that the vasodilatory action induced by NO could further accelerate hemodynamic collapse [20]. Notably, unlike MSN@LA which predominantly lowered the blood pressure, PCM-MSN@LA, in response to LIFU irradiation, quickly entered and accumulated in the septic cardiomyocytes, whereas, at the same time avoided the collapse of blood pressure. Thus, precise myocardium-targeting of NO-producing nanoparticles could successfully avoid the side effects of NO diffusion during myocardial protection.

Unfortunately, it is still challenging to monitor the ultrasound imaging-guided gas delivery in vivo with currently available technologies. The comprehensive process of NO liberation to the heart remains to be investigated and addressed in future.
Conclusions
Overall, the myocardial delivery of NO donor was accomplished by the PCM conjugation plus LIFU guided strategy designed and described in this context. Responding to the infective microenvironment, the PCM-MSN@LA executed a successful generation of NO at a balanced low level in the heart. This precise gas therapy showed excellent benefits in myocardial recovery from sepsis. Our design provides a novel therapeutic strategy with great promise to treat sepsis-induced myocardial injury.

Methods
Synthesis of PCM-MSN@LA
3-aminopropyltriethoxysilane (APTS), N-Cetyltrimethyl ammonium bromide (CTAB, 99%), N-hydroxysuccinimide (NHS, 98%) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, >97%) were purchased from Alfa Aesar (Tianjin, China). HCl solution (37%) and sodium hydroxide (NaOH) were obtained from Xilong (Guangdong, China). The FITC-labeled PCM and scrambled peptide ligands were synthesized by Sangon Biotech Co., Ltd (Shanghai, China) as follows: PCM, DPVWEYPLEFSWDTGWGDSS; scramble, WLSEAGPVVTRALRGTGSW. To make MSN, firstly 1.0 g of CTAB (2.74 mmol) and 3.5 mL of NaOH solution (2 mmol) were dissolved in 520 mL of deionized water and heated to 80 °C, followed by the addition of 5.0 mL TEOS solution dropwise. The mixture solution was then stirred at 80 °C for 2 h. After 10 min centrifugation at 8700 g, the crude product was isolated and washed thoroughly with water and ethanol for three times. To remove CTAB, 0.7 g of the crude sample was dissolved in a mixture of ethanol (70 mL) and concentrated HCl (0.70 mL, 37.2%). Sixteen hours later, the organic solvent was rinsed using deionized water at least 3 times to obtain MSN. One gram of MSN was dissolved in 100 mL of anhydrous toluene via sonication, which was then incubated with 1 mL of APTS for 20 h. White particles were collected through centrifugation and sequentially washed three times with ethyl alcohol and deionized water, respectively. Following CTAB removal with 0.8 mL of HCl at 80 °C for 16 h, MSN-NH2 nanoparticles were obtained via lyophilization.

Subsequently, 100 mg of MSN-NH2 was dispersed in 20 mL of PBS with 0.03 mg of N-hydroxysuccinimide (NHS) and 0.3 mg of a 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and stirred overnight at room temperature. PEG-MSN-NH2 was prepared with PEG co-incubation for 12 h via amidation. FITC-labeled scrambled peptide or FITC-labeled PCM in DMSO was incubated with PEG-MSN-NH2 for 28 h. The residue was extracted by centrifugation in 1000 pcf at room-temperature for 10 min three times and dried via lyophilization. PCM-MSN@LA nanoparticles were prepared using 20 mg of PCM-MSNs dispersed in 10 mL of saturated LA solution and incubated in the dark for 20 h, and then washed for 3 times with deionized water followed by vacuum drying.

A total of 1 mg of PCM-MSN@LA was resuspended in 1 mL of PBS and stored at 4 °C before use.

Characterization of PCM-MSN@LA
The features of PCM-MSN@LA nanoparticles including size, zeta, FTIR and morphology were assessed by DLS (Malven Zetasizer, Nano ZS90), infrared spectrometry (Nicolet, Avatar360) and transmission electron microscopy (TEM, FEI, TecnaiG2F20). Peptide conjugation and LA encapsulation were confirmed by thermal gravimetric analysis (Setaram, S60/51920). The mean size and zeta of nanoparticles were measured using DLS from day 0 to 28 for stability testing.

L-arginine loading and L-arginine release using LIFU in vitro
Five milliliters of PCM-MSNs dispersed in 10 mL of saturated LA solution and incubated in the dark for 20 h, and then washed for 3 times with deionized water followed by vacuum drying.

LA solution and incubated in the dark for 20 h, and then washed for 3 times with deionized water followed by vacuum drying. The function of LA molecules was indicated by the absorbance intensities of LA according to a standard curve.

Primary cardiomyocyte isolation
All animal experiments were approved by the Institutional Animal Care and Use Committee of Central South University (Changsha, China).

Cardiac tissue from 1-day-old C57/BL6 neonates were purchased from Hunan SJA Laboratory Animal Co., Ltd. (Hunan, China). To isolate cardiomyocytes, the heart was digested with 2.5 mg mL−1 trypsin (Aladdin Co., Ltd, Shanghai, China) and perfused with digestion buffer containing 2 mg mL−1 DNase I (Sigma, D7291). The cardiomyocytes were collected from the tissue piece suspension upon centrifugation and cultured in DMEM (HyClone, C11995500BT) containing 20% FBS (Biological
Industries, 04-001-1ACS), 40 IU mL⁻¹ penicillin (Sigma, P3032), 1.6 μg mL⁻¹ VitB12. (Sigma, V6629) and 0.1 mmol L⁻¹ 5'-bromo-2'-deoxyuridine (Sigma, B5002) at 37 °C, 5% CO₂, 21% O₂ and 74% N₂.

Male C57/BL6 mice aged 8 to 12 weeks (range 20–30 g) were purchased from Hunan SJA Laboratory Animal Co., Ltd. (Hunan, China), housed and maintained at room-temperature in an air-conditioned environment.

The safety of PCM-MSN@LA

The changes in particle size and zeta from day 0 to 28 were measured using DLS.

Cell counting Kit 8 (CCK-8)
Cardiomyocytes were seeded in 96-well plates at a density of 1 × 10⁴ cells/well and cultured for 24 h. PCM-MSN@LA was added into the cells in triplicate at various concentrations of 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, and 1 mg mL⁻¹, respectively. After incubating for 24 h, the cells were collected and stained with a CCK-8 proliferation kit (Dojindo, CK04) The absorbance was measured at 450 nm.

Hematoxylin–eosin (HE) staining
The organs, including the lung, liver, spleen, kidney, and heart, were isolated from C57/BL6 before and 24 h post 50 mg kg⁻¹ PCM-MSN@LA injection. After 3–5 times of rinses with saline, some parts of each organ were fixed with 10% formalin and embedded in paraffin. Paraffin sections (≤5 μm) were stained with hematoxylin and eosin (HE) at 37 °C for 15 min. The slides were examined under a light microscope (Carl Zeiss AG, Oberkochen, Germany) at a magnification of 40 × 10.

Evaluation of cell uptake and biodistribution of the targeted NO release system in the myocardium
To evaluate nanoparticle biodistribution, Cy5.5 fluorescent dye was used to replace L-arginine along with unstained PCM and scramble peptides. To demonstrate the specific binding ability of PCM to cardiomyocytes, cardiomyocytes treated with scrambled peptide-MSNs and HepG2 cells treated with PCM-MSNs were used as controls.

Cell colocalization staining
Both cardiomyocytes and HepG2 were seeded in 6-well plates at a density of 1 × 10⁴ cells per well. The cardiomyocytes were incubated with fresh DMEM containing 50 μg mL⁻¹ PCM-MSN and scrambled peptide-MSNs, respectively, whereas HepG2 cells incubated with PCM-MSN only, for 1 h. After discarding the culture media, the cells were washed with PBS (pH 7.40) three times before 0.1% Triton X-100 permeabilization and 4% paraformaldehyde fixation. All cells were firstly stained with R-PE conjugated anti-sarcomeric alpha actinin (α-SA) (Abcam, 137346, 1:100) at 4 °C for overnight for cardiomyocyte-specific labeling [17]. After washing, the cells were counterstained with 4′6-diamidino-2-phenylindole (DAPI) (Sigma, D9542) at room temperature for 15 min. Cardiomyocyte internalization was assessed using a confocal laser scanning microscope (CLSM, Olympus Fluoview FV3000). The fluorescence intensity was graphed according to the white line of merged fluorescence images.

In vivo fluorescence imaging
Three groups of mice (4 mice each), MSN, PCM-MSN, and PCM-MSN + LIFU, were assessed for myocardial binding efficiency. After anesthetization with 1% pentobarbital sodium (50 mg kg⁻¹), each type of nanoparticle solution was injected via the tail vein at a dose of 50 mg kg⁻¹. The transducers were placed at the heart 1 min later. Ultrasound was transmitted at 1.0 W/cm² 20% duty power for 10 s per cycle, 10 cycles, 10 s intervals. Six hours later, the organs, including the heart, lungs, spleen, liver and kidneys, were isolated and rinsed with PBS for multiple times to wash away the blood. The distribution of fluorescence signal was visualized with in vivo imaging (PerkinElmer, IVIS lumina III). Heart cryosections (2 mm thickness) were prepared simultaneously to further assess nanoparticle localization in the cardiac. Quantitative analysis was performed using the Living Image 5.0 software.

Measurement of intracellular NO release
Cardiomyocytes were cultured in DMEM with 10% FBS and 1% penicillin/streptomycin at a density of 1 × 10⁶ cells/well in a 6-well plate. The sepsis model was established by incubating the cells with 1 μg mL⁻¹ LPS (Sigma, Escherichia coli, O111:B4), which was then added with PCM-MSN@LA at a concentration of 25, 50, 75 and 100 μg mL⁻¹, respectively. Untreated cardiomyocytes with 25 or 50 μg mL⁻¹ of PCM-MSN@LA were set up as control. Nitrite levels were measured with 1 mL of supernatant taken from each group at 2 h after treatment using a Griess assay kit (Beyotime Biotechnology, S0021, Haimen, China) on an ultraviolet spectrophotometer (Shimadzu, UV2700, Japan). For dynamic monitoring of NO generation in LPS-treated cardiomyocytes, the cells were incubated with 75 μg mL⁻¹ PCM-MSN@LA and LIFU (1.0 W/cm², 20% duty power-10 s per cycle-10 cycles) was carried out at the bottom of the plate. The NO fluorescent probe DAF-FM DA (Beyotime Biotechnology, S0019) was added at different time points (pre,
5 min, 15 min, 30 min, 2 h and 6 h) and incubated with the cells at 37 °C for 20 min in darkness. Then the media was removed and the cells were washed 3 times with PBS. The fluorescence intensity in cardiomyocytes was measured by CLSM (Olympus FluoView FV3000) and quantified as nitrite levels.

Cardiomyocytes viability and superoxide assessment.
In total, cardiomyocytes were prepared in 5 groups as Table 1 with various treatments. After 6 h, all cells were analyzed with a CCK-8 proliferation kit and the absorbance was measured at 450 nm.

Ultrasound parameters
1.0 W/cm²–20% duty power, 10 cycles of 10 s irradiation with 10 s intervals

TUNEL staining (Beyotime Biotechnology, C1091) and DCFH-DA staining (Beyotime Biotechnology, S0033) were also conducted with cardiomyocytes seeded in 35 mm dishes with 0.17 mm thickness (Nest, N801001) at a density of $1 \times 10^4$ cells per well after 24 h’ culture followed by treatments listed in Table 1 for 6 h. The cells were examined by laser confocal microscopy. The number of positive cells was calculated by Image-Pro Plus software version 6.0 (Media Cybernetics, Bethesda, MD).

In vivo myocardium-targeted NO production
An endotoxic shock animal model was established with C57/BL6 mice. Lipopolysaccharide was dissolved in sterile PBS to a final concentration of 5 mg ml⁻¹ (LPS). Pentobarbital sodium-anesthetized C57/BL6 mice were administered with 0.5 mL of PBS and LPS (10 mg kg⁻¹ body weight), respectively, via intraperitoneal injection, followed by immediate subcutaneous injection of 1 mL saline (prewarmed to 37 °C) for fluid resuscitation. All measurements were conducted and samples were taken at 6 h after treatment unless otherwise indicated.

In total, 48 mice were divided into six groups as Table 2: LIFU was applied at 1 min after the last injection as follows: 1.0 W/cm²–20% duty power, 10 cycles of 10 s per cycle with 10 s intervals.

There were 36 mice divided additionally into six groups as listed in Table 2 for examining survival rates.

Measurement of blood cell markers
Levels of LDH, CK-MB and cTnI were measured with samples collected from the inferior vena cava and centrifuged at 589 g min⁻¹ for 10 min, 4 °C. Plasma concentrations of LDH and CK-MB were measured using an automatic biochemical analyzer (Hitachi, 7600), whereas cTnI was measured by a Quantikine mouse ELISA kit (Cusabio, CSB-E08421).

Measurement of blood pressure
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were monitored using the P-600A automatic noninvasive blood pressure measurement system (TECHMAN, Chengdu, China). During the 6-h treatment, all mice had been placed on the receiver pad of a tail-cuff device with synchronized instrument clocks. All data have been recorded throughout the process.

Echocardiography
Echocardiography was performed at 6 h after CLP under light anesthesia with 2% isoflurane inhalation via an isoflurane delivery system. All images were obtained from an ultrasound scanner (FujiFilm, Visual Sonics Vevo 2100) coupled with a 30.0-MHz linear transducer. Left ventricular (LV) diameters at end-diastole and end-systole (LVEDD/LVESD) were measured from M-mode images in the short-axis view at the papillary muscle level. LV systolic function-fraction shortening (FS) and ejection fraction (EF) were calculated using Visual Sonics Measurement Software. Left ventricular volumes at end-diastole and end-systole (LV VOL d/LV VOL s) were evaluated using improved Simpson’s method by tracing the endocardium manually on the apical two Chamber view at end-diastole and end-systole for 3 cardiac cycles.

---

**Table 1** Viability and superoxide assessment

| Group | Name          | Treatment*                                      |
|-------|---------------|------------------------------------------------|
| 1     | Control       | None                                           |
| 2     | LPS           | LPS                                            |
| 3     | PCM-MSN       | PCM-MSN+LPS                                    |
| 4     | PCM-MSN@LA    | PCM-MSN@LA+LPS                                 |
| 5     | PCM-MSN@LA+LIFU | PCM-MSN@LA+LPS, with LIFU irradiation          |

*LPS: 5 μg mL⁻¹, PCM-MSN@LA: 75 μg mL⁻¹

**Table 2** In vivo NO production assessment

| Group | Name          | Treatment*                                      |
|-------|---------------|------------------------------------------------|
| 1     | Control       | Saline                                         |
| 2     | LPS           | LPS                                            |
| 3     | PCM-MSN       | PCM-MSN+LPS                                    |
| 4     | MSN@LA        | MSN@LA+LPS                                     |
| 5     | PCM-MSN@LA    | PCM-MSN@LA+LPS                                 |
| 6     | PCM-MSN@LA+LIFU | PCM-MSN@LA+LPS, with LIFU irradiation          |

*PCM-MSN, MSN@LA and PCM-MSN@LA were all administrated at a dosage of 1 mg kg⁻¹ for 2 min before LPS injection
**Histopathological assessment**

Mouse heart tissue was fixed in 4% paraformaldehyde and paraffin-embedded before cutting into 5-μm sections for HE staining as mentioned above.

**Electron microscopy assay**

Mouse heart tissue was dissected into multiple slices with 1 mm thickness and fixed in 2.5% glutaraldehyde. After additional fixation in 1% osmium tetroxide (OsO4; Sinopharm Chemical Reagents Co., Ltd., Shanghai, China) for 1 h at room temperature, the sections underwent transmission electron microscopic examination (ZEISS 906, Germany).

**Immunohistochemistry examination**

To assess apoptosis, frozen mouse heart slides with 4-μm thickness were prepared in 15% sucrose at 4 °C. After blocking with avidin (Leagene Biotechnology Co., Ltd., Beijing, China) at room temperature for 20 min, the tissue samples were conducted with TUNEL staining following the manufacturer’s instructions (KeyGEN BioTECH Co., Ltd., Jingsu, China). immune cells were stained using anti-rat Ly-6G antibody (Abcam, ab25377, 1:50) and goat anti-rat IgG secondary antibody (Life Technologies GmbH, Darmstadt, A10517, 1:200). Sections were washed 5 times and developed with a 3,3′-diaminobenzidine kit (DAB). All slides were counterstained with hematoxylin and examined by light microscopy (NIKON, ECLIPSE C1, Japan).

**Immunofluorescence staining**

Cellular reactive oxygen species were measured in mouse heart sections by dihydroethidium (DHE) labeling according to the manufacturer’s instructions. After DHE (Sigma, D7008) staining for 30 min followed by DAPI staining for 5 min at 37 °C in darkness, the slides were analysed and imaged by fluorescence microscopy (Nikon Eclipse C1, Nikon, Japan).

**Malondialdehyde (MDA) measurement**

MDA is a stable metabolite of lipid peroxidation products. Heart samples were homogenized in 60 mL of PBS (pH 6). Tissue homogenate (0.1 mL) was mixed well with 0.2 mL MDA colorimetric reagent (Beyotime Biotechnology, S0131S). The mixture was incubated at 100 °C for 15 min in a water bath and then centrifuged for 10 min at room temperature. The absorbance at 532 nm was measured using a spectrophotometer (Cecil Instruments, Ltd., CE 9000, UK).

**Western blot**

Western blot was performed using mouse heart tissue homogenates with primary antibodies including iNOS (Abcam, 178945, 1:1000), eNOS (Abcam, 199956, 1:1000), NLRP3 (Adipogen, AG-20B-0014, 1:1000), NF-κB P65 (Cell Signaling Technology, 8242, 1:1000) and Cleaved-caspase3 (C-caspase3) (Cell Signaling Technology, 9964, 1:1000), and HRP-conjugated secondary antibodies. All images were developed via an ECL system (Amersham Biosciences, USA). Tubulin (Proteintech, 10094-1-AP, 1:5000) or GAPDH (Proteintech, 10494–1-AP 1:10000) antibody was used as an internal control.

**Real-time PCR**

Total RNA was extracted using RNAiso Plus (Takara), from each sample. cDNA was synthesized using the QuantScript RT Kit (TIANGEN) according to the manufacturer’s protocol. The levels of gene expression were amplified using PowerUp SYBR Green Master Mix and analyzed by one-step RT-qPCR. The levels of gene expression were determined using the comparative Ct method and normalized to GAPDH. The oligonucleotide primers for IL-1β, IL-6, IL-18, TNF-α, and GAPDH are shown in Table 3.

**Statistical analysis**

Data were analysed using GraphPad Prism 5.0 software. Data are presented as the mean ± standard deviation (SD) in all of the experiments (n = 3). One-way ANOVA followed by Student’s t test was performed to determine the P values (95% confidence interval). Survival rates were evaluated with the log-rank test. The asterisks indicate statistical significance; unless otherwise specified, *P < 0.05, **P < 0.01.
Acknowledgements
We would like to thank the Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Hunan Normal University and the Laboratory of Cardiovascular Medicine Research of Second Xiangya Hospital for the assistance during particle structure characterizations.

Author contributions
MO and ZZ conceived and designed the experiments. MO wrote the manuscript. XO and ZP executed the experiments, analyzed the data. GX, QS, and MO and ZZ assisted during particle structure characterizations.

Funding
This work was supported by grants from the National Natural Science Foundation of China (81801721), Natural Science Foundation of Hunan province (2021JJS0223), China Postdoctoral Science Foundation (2021M700318), China Postdoctoral Science Foundation (2021M690318), and the Laboratory of Chemical Biology & Traditional Chinese Medicine Research of Second Xiangya Hospital for the assistance during particle structure characterizations.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
All institutional and national guidelines for the care and use of laboratory animals were followed. All the animal care and experimental protocols were carried out with review and approval from the Laboratory Animal Welfare and Ethics Committee of Central South University.

Consent for publication
All authors agree to be published.

Competing interests
The authors declare no conflict of interest.

Author details
1 Department of Ultrasound Diagnosis, Second Xiangya Hospital, Central South University, Changsha 410011, China. 2 Department of Ultrasound, Hunan Provincial People's Hospital, The First Affiliated of Hunan Normal University, No. 61 Jiefang Road (W), Changsha, China. 3 Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of Education, College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha 410081, China.

Received: 21 February 2022 Accepted: 7 May 2022
Published online: 07 June 2022

References
1. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010;376:1339–46.
2. Rudd KE, Johnson SC, Agessa KM, Shackelford KA, Tao D, Kivel VN, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–11.
3. Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, et al. Development and validation of the ISARIC 4C deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respir Med. 2021;9:349–59.
4. Lin H, Wang W, Lee M, Meng Q, Ren H. Current status of septic cardiomyopathy: basic science and clinical progress. Front Pharmacol. 2020;11:210.
5. Ehman RR, Moore SC, Favor MJ, Akers KG, Gallien JZ, Welch RD, et al. Scientific letter to the editor: need for a definitive study of global longitudinal strain for prognostication in septic cardiomyopathy. J Am Soc Echocardiogr. 2019;32:549–52.e3.
6. Ehman RR, Sullivan AN, Favor MJ, Shervin RL, Reynolds CA, Abidov A, et al. Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature. Crit Care. 2018;22:112.
7. Martin L, Derwall M, Al Zoubi S, Zechendorf E, Reuter DA, Thiemermann C, et al. The septic heart: current understanding of molecular mechanisms and clinical implications. Chest. 2019;155:427–37.
8. Khambata RS, Ghosh SM, Rathod KS, Thevathasan T, Filomena F, Xiao Q, et al. Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque. Proc Natl Acad Sci U S A. 2017;114:E550–9.
9. Kim YM, Talanian RV, Li J, Billiar TR. Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). J Immunol. 1998;161:4122–8.
10. Carlstrom M, Montenegro MF. Therapeutic value of stimulating the nitrate-nitrite-nitric oxide pathway to attenuate oxidative stress and restore nitric oxide bioavailability in cardiorenal disease. J Intern Med. 2019;285:2–18.
11. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
12. Beeley SJ, Weber G, Sarge T, Nkravan S, Grissom CK, Larspa MJ, et al. Septic cardiomyopathy. Crit Care Med. 2018;46:625–34.
13. Huang Z, Fu J, Zhang Y. Nitric oxide donor-based cancer therapy: advances and prospects. J Med Chem. 2017;60:7617–35.
14. Mousavizadeh A, Jabbari A, Akrami M, Bardania H. Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: a systematic review. Colloids Surf B Biointerfaces. 2017;158:507–17.
15. McGuire MJ, Samii KN, Johnston SA, Brown KC. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol. 2004;342:171–82.
16. Zhao X, Luo W, Hu J, Zuo L, Wang J, Hu R, et al. Cardiomyocyte-targeted and 17beta-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy. J Nanobiotechnology. 2018;16:36.
17. Sun Z, Xie Y, Lee RJ, Chen Y, Jin Q, Lv Q, et al. Myocardium-targeted transplantation of PHD2 shRNA-modified bone mesenchymal stem cells through ultrasound-targeted microbubble destruction protects the heart from acute myocardial infarction. Theranostics. 2020;10:4967–82.
18. Liu J, Shang T, Wang F, Cao Y, Hao L, Ren J, et al. Low-intensity focused ultrasound (LIFU)-induced acoustic droplet vaporization in phase-transition perfluoropentane nanodroplets modified by folate for ultrasound molecular imaging. Int J Nanomedicine. 2017;12:911–23.
19. Wang Y, Sui G, Teng D, Wang Q, Ji Z, Zhu L, et al. Low intensity focused ultrasound (LIFU) triggered drug release from cettuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma. Biomater Sci. 2018;7:196–210.
20. Li M, Li J, Chen J, Liu Y, Cheng X, Yang F, et al. Platelet membrane biomimetic magnetic nanocarriers for targeted delivery and in situ generation of nitric oxide in early ischemic stroke. ACS Nano. 2020;14:2024–35.
21. Yang F, Li M, Liu Y, Wang T, Feng Z, Cui H, et al. Glucose and magnetic-responsive approach toward in situ nitric oxide bubbles controlled generation for hyperglycemia theranostics. J Control Release. 2016;228:87–95.
22. Zhang K, Xu H, Jia X, Chen Y, Ma M, Sun L, et al. Ultrasound-triggered nitric oxide release platform based on energy transformation for targeted inhibition of pancreatic tumor. ACS Nano. 2016;10:18061–28.
synergistic cancer starving-like/gas therapy. Angew Chem Int Ed Engl. 2017;56:1229–33.

24. Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15:292–316.

25. Jackson J, Patterson AJ, MacDonald-Wicks L, McCvay M. The role of inorganic nitrate and nitrite in CVD. Nutr Res Rev. 2017;30:247–64.

26. Andrade EB, Kaltcheva V, Weitz B. Self-disclosure on the Web: The impact of privacy policy, reward, and company reputation. Adv Consum Res. 2002;29:350–3.

27. Sakaguchi A, Kimura W. Metabolic regulation of cardiac regeneration: roles of hypoxia, energy homeostasis, and mitochondrial dynamics. Curr Opin Genet Dev. 2021;70:54–60.

28. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015;14:623–41.

29. Rana S, Datta K, Reddy TL, Chatterjee E, Sen P, Pal-Bhadra M, et al. A spatio-temporal cardiomyocyte targeted vector system for efficient delivery of therapeutic payloads to regress cardiac hypertrophy abating bystander effect. J Control Release. 2015;208:167–78.

30. Kanki S, Jiaalouk DE, Lee S, Yu AY, Gannon J, Lee RT. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol. 2011;50:841–8.

31. Zhao YZ, Zhang M, Wang HL, Tian XQ, Zheng L, Yu XC, et al. Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique. J Control Release. 2016;223:11–21.

32. Dezfuleian C, Shiva S, Aleksyenko A, Pendyal A, Beiser DG, Munasinghe JP, et al. Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I. Circulation. 2009;120:897–905.

33. Thomas DD, Ridnour LA, Ilsenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med. 2008;45:18–31.

34. Cauwels A, Buys ES, Thoonen R, Geary L, Delanghe J, Shiva S, et al. Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med. 2009;208:2915–24.

35. Sui Y, Tian R, Lu N. NADPH oxidase is a primary target for antioxidant effects by inorganic nitrite in lipopolysaccharide-induced oxidative stress in mice and in macrophage cells. Nitric Oxide. 2019;89:46–53.

36. Qian J, Chen F, Kovalenkov Y, Pandey D, Foster MW, et al. Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation. Free Radic Biol Med. 2012;52:1806–19.

37. Bryan NS, Calvert JW, Gundewar S, Lefer DJ. Dietary nitrite restores NO homeostasis and is cardioprotective in endothelial nitric oxide synthase-deficient mice. Free Radic Biol Med. 2008;45:468–74.

38. Graham DB, Jasso C, Mok A, Goel G, Ng ACY, Koldel R, et al. Nitric oxide engages an anti-inflammatory feedback loop mediated by peroxiredoxin 5 in phagocytes. Cell Rep. 2018;24:838–50.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.